CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 63 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $356,019 | +89.4% | 11,971 | +14.8% | 0.00% | 0.0% |
| Q2 2023 | $187,967 | -8.5% | 10,431 | -7.0% | 0.00% | 0.0% |
| Q4 2022 | $205,363 | +0.7% | 11,222 | +8.9% | 0.00% | 0.0% |
| Q3 2022 | $204,000 | +8.5% | 10,309 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $188,000 | -36.9% | 10,079 | -25.7% | 0.00% | 0.0% |
| Q1 2022 | $298,000 | -37.4% | 13,559 | -19.1% | 0.00% | 0.0% |
| Q4 2021 | $476,000 | +73.7% | 16,755 | +28.5% | 0.00% | 0.0% |
| Q3 2021 | $274,000 | -10.5% | 13,034 | -19.6% | 0.00% | 0.0% |
| Q2 2021 | $306,000 | +70.0% | 16,217 | +37.6% | 0.00% | 0.0% |
| Q1 2021 | $180,000 | +15.4% | 11,786 | +6.4% | 0.00% | 0.0% |
| Q4 2020 | $156,000 | -24.6% | 11,075 | +21.7% | 0.00% | 0.0% |
| Q1 2019 | $207,000 | -22.2% | 9,098 | +2.4% | 0.00% | -50.0% |
| Q4 2018 | $266,000 | – | 8,881 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $76,819,000 | 7.66% |
| RA Capital Management | 1,875,209 | $42,680,000 | 1.84% |
| Perceptive Advisors | 2,587,953 | $58,901,000 | 1.66% |
| EMORY UNIVERSITY | 97,035 | $2,209,000 | 1.55% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $3,817,000 | 1.05% |
| Orbimed Advisors | 1,914,282 | $43,569,000 | 0.67% |
| Opaleye Management Inc. | 73,000 | $1,661,000 | 0.46% |
| Novo Holdings A/S | 135,009 | $3,073,000 | 0.46% |
| Virtus ETF Advisers LLC | 7,934 | $181,000 | 0.38% |
| Eventide Asset Management | 384,000 | $8,740,000 | 0.30% |